The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

No abstract is available for this paper.

• Publication year

  2006

• Venue

  British Journal of Pharmacology

• Publication date

  2006-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/sj.bjp.0706716PMID 16547525PMCID PMC1617064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chapter 5 – Agonists: The Measurement of Affinity and Efficacy in Functional Assays

  2006cited by this paper
• In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4–11) (UFP‐803)

  2006influential reference
• The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats

  2006cited by this paper
• Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors.

  2005cited by this paper
• Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

  2005cited by this paper
• Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.

  2005cited by this paper
• Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats.

  2005cited by this paper
• Urotensin-II receptor ligands. From agonist to antagonist activity.

  2005cited by this paper
• Structure–activity relationship study on human urotensin II

  2005cited by this paper
• Cloning and pharmacological characterization of the cat urotensin-II receptor (UT).

  2005influential reference
• Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II–Mediated Vasoconstriction

  2005cited by this paper
• Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375

  2005influential reference
• BacMam recombinant baculoviruses in G protein-coupled receptor drug discovery.

  2004cited by this paper
• Urotensin II in the cardiovascular system.

  2004cited by this paper
• Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.

  2004cited by this paper
• Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

  2004influential reference
• Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.

  2004influential reference
• Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators

  2004cited by this paper
• From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

  2004cited by this paper
• Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.

  2004influential reference
• Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.

  2004cited by this paper
• Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats.

  2004cited by this paper
• Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure

  2004cited by this paper
• Emerging roles of urotensin-II in cardiovascular disease.

  2004cited by this paper
• Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.

  2004cited by this paper
• Cardiovascular role of urotensin II: effect of chronic infusion in the rat.

  2004cited by this paper
• Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response

  2004cited by this paper
• Urotensin-II: a novel systemic hypertensive factor in the cat

  2004influential reference
• Pharmacology of the Urotensin-II Receptor Antagonist ACT-058362: First Demonstration of a Pathophysiological Role of the Urotensin System

  2004cited by this paper
• Identification and pharmacological characterization of native, functional human urotensin‐II receptors in rhabdomyosarcoma cell lines

  2004cited by this paper
• Heterologous expression of G protein-coupled receptors in U-2 OS osteosarcoma cells.

  2004cited by this paper
• The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors

  2003influential reference
• International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology

  2003cited by this paper
• Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

  2003cited by this paper
• Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy

  2003cited by this paper
• Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone‐inducible mammalian expression system

  2003cited by this paper
• Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta

  2003influential reference
• A guide to drug discovery: Predicting therapeutic value in the lead optimization phase of drug discovery

  2003cited by this paper
• Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

  2003cited by this paper
• Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice

  2003cited by this paper
• Octreotide antagonizes the urotensin II (U II) induced aortic contractions in normal and cirrhotic rats

  2003cited by this paper
• Effects of single bolus urotensin II injection on renal function in anaesthetised rats

  2003cited by this paper
• Chapter 11. Urotensin-II receptor modulators

  2003cited by this paper
• Urotensin II evokes potent vasoconstriction in humans in vivo

  2002cited by this paper
• Efficacy at g-protein-coupled receptors

  2002cited by this paper
• Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey

  2002cited by this paper
• A new ligand for the urotensin II receptor

  2002influential reference
• Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist

  2002influential reference
• Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats

  2001cited by this paper
• Novel urotensin II (UII) antagonists point to multiple receptor involvement in UII bioactivity

  2000cited by this paper
• Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

  2000influential reference
• Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999influential reference
• International Union of Pharmacology. XIX. The IUPHAR receptor code: a proposal for an alphanumeric classification system.

  1998cited by this paper
• Functional receptors for fish neuropeptide urotensin II in major rat arteries.

  1988cited by this paper
• Operational models of pharmacological agonism

  1983cited by this paper
• Is prenalterol (H133/80) really a selective beta 1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships.

  1980cited by this paper
• Is intra-arterial 5-hydroxytryptamine a potent algogenic substance in the dog?

  1974cited by this paper

• Urotensin-II receptor contributes to the pro-inflammatory TLR4/MyD88/NF-κB/iNOS/NO pathway-mediated cardiovascular response to systemic lipopolysaccharide challenge in a septic shock model in rats.

  2025cites this paper
• The urotensin II receptor triggers an early meningeal response and a delayed macrophage-dependent vasospasm after subarachnoid hemorrhage in male mice

  2024cites this paper
• EXPLORATION OF THE UROCONTRIN A SCAFFOLD YIELDS NEW UROTENSINERGIC SYSTEM ALLOSTERIC MODULATOR AND COMPETITIVE ANTAGONISTS.

  2023cites this paper
• Novel insights into the role of urotensin II in cardiovascular disease.

  2019cites this paper
• Towards Targeting the Urotensinergic System: Overview and Challenges.

  2019cites this paper
• Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist.

  2016cites this paper
• International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

  2015cites this paper
• Antagonists, partial agonists and inverse agonists of the urotensin II receptor for use in the prevention of neurological deficits consecutive has a subarachnoid haemorrhage

  2013cites this paper
• Discovery of new antagonists aimed at discriminating UII and URP‐mediated biological activities: insight into UII and URP receptor activation

  2013cites this paper
• Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures

  2013cites this paper
• Eff ects of Urotensin II and Its Specifi c Receptor Antagonist Urantide on Rat Vascular Smooth Muscle Cells

  2013cites this paper
• Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells.

  2013cites this paper
• In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands

  2012cites this paper
• Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.

  2012cites this paper
• In Vitro Manipulation of Urotensin-II Receptor Expression: Implications of Receptor Density on Ligand Efficacy

  2011influential citation
• Baculovirus gene delivery: a flexible assay development tool.

  2010cites this paper
• A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects

  2010cites this paper
• GSK1562590, a slowly dissociating urotensin‐II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo

  2010cites this paper
• Pharmacological Applications of Baculovirus‐Mediated Protein Expression in Mammalian Cells

  2010cites this paper
• Viral-mediated gene delivery for cell-based assays in drug discovery

  2009cites this paper
• BacMam: versatile gene delivery technology for GPCR assays.

  2009cites this paper
• Identification of new agonists of urotensin-II from a cyclic peptide library.

  2009cites this paper
• Human urotensin-II receptor desensitisation

  2009cites this paper
• Development of Multiplexed Microarray Binding Assays for High-Throughput Drug Discovery

  2009cites this paper
• Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?

  2008cites this paper
• Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Nonfailing Human Myocardium

  2008cites this paper
• [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes.

  2008cites this paper
• 2-Aminomethyl piperidines as novel urotensin-II receptor antagonists.

  2008cites this paper
• Hemodynamic-independent anti-natriuretic effect of urotensin II in spontaneously hypertensive rats.

  2008cites this paper
• Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues

  2008cites this paper
• Structure-activity relationships of urotensin II and URP.

  2008cites this paper
• The baculovirus display technology--an evolving instrument for molecular screening and drug delivery.

  2008cites this paper
• Structure–activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11)

  2008cites this paper
• Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.

  2008cites this paper
• The Urotensin II System in Ischaemic Myocardial Dysfunction.

  2008cites this paper
• BacMam technology and its application to drug discovery

  2007cites this paper
• Implementation of BacMam virus gene delivery technology in a drug discovery setting.

  2007cites this paper
• Role of urotensin II and its receptor in health and disease

  2007cites this paper
• Baculoviruses and mammalian cell-based assays for drug screening.

  2006cites this paper
• Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist.

  2006cites this paper